VASTox plc
06 October 2006



                                   VASTox plc
                          ("VASTox" or "the Company")


             VASTOX PLC HOSTS R&D DAY TO HIGHLIGHT KEY DEVELOPMENTS


Oxford, UK, 6 October 2006 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, today hosts an R&D day for analysts and investors from 10:45hrs at its
main site in Milton Science Park, near Oxford.

Key members of the senior management team will make presentations aimed at
improving awareness and understanding of the Company, its chemical genomic
technology platforms and therapeutic programmes, in particular its lead
programme in Duchenne Muscular Dystrophy (DMD).

Also, a presentation on the broader issues of the impact of DMD in the community
will be given by Nick Catlin, CEO of Parent Project UK (PPUK). PPUK is the only
national charity that exclusively funds research and campaigns for better
medical care for Duchenne and Becker muscular dystrophy.

For details of the presentations given today, please contact VASTox directly at
investors@vastox.com or Citigate Dewe Rogerson (details below).


                                    - ends -



For more information please contact:


VASTox

Steven Lee, PhD, Chief Executive Officer           Tel: +44 (0)1235 443910

Darren Millington, ACMA, Chief Financial Officer


Citigate Dewe Rogerson                             Tel: +44 (0)207 638 9571

David Dible / Mark Swallow / Valerie Auffray       Mobile: +44 (0)7903 737703

                                                   mark.swallow@citigatedr.co.uk



About VASTox plc


VASTox is a biotechnology company that discovers and develops proprietary novel
drugs and provides services to the pharmaceutical industry. The company's most
advanced drug development programme is focused on developing a new treatment for
Duchenne muscular dystrophy based on the up-regulation of utrophin. A second
drug development programme for spinal muscular atrophy is also progressing
rapidly. VASTox has four additional programmes focused on osteoarthritis,
cancer, tuberculosis and stem cell therapies, which are expected to be
out-licensed prior to entering the clinic.

The company's technology platform, which uses zebrafish and fruitflies, has the
potential to dramatically decrease the time and cost of drug discovery and
development. This is because using whole organisms allows it to carry out high
volume, high content screening, which delivers data that are highly predictive
of the efficacy and toxicity of potential drug compounds in humans. VASTox is
growing revenues based on marketing its unique technology platform and its
chemistry expertise.  The company listed on the AIM market of the London Stock
Exchange in October 2004.

Further information about the company is available at www.vastox.com



                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRAMGMGGNKNGVZM